Pre FDCAsa
N= 1,654  (%)
Post FDCAsa
N=1,064  (%)
pb TOTAL
N=2,718  (%)
Reverse transcriptasa
M184V/I 823 (49.8) 433 (40.7) <0.0001 1,256 (46.2)
T215Y/F 675 (40.8) 268 (25.2) <0.0001 943 (34.7)
M41L 572 (34.6) 212 (19.9) <0.0001 784 (28.8)
D67N 421 (25.5) 167 (15.7) <0.0001 588 (21.6)
L210W 393 (23.8) 146 (13.7) <0.0001 539 (19.8)
K70R 291 (17.6) 136 (12.8) 0.001 427 (15.7)
K219Q/E 274 (16.6) 138 (13.0) 0.01 412 (15.2)
L74V 180 (10.9) 67 (6.4) <0.0001 247 (9.2)
K65R 119 (7.2) 52 (4.9) 0.01 171 (6.3)
TAMSc 915 (55.3) 367 (34.5) <0.0001 1,282 (47.2)
K103N 512 (31.0) 245 (23.0) <0.0001 773 (27.9)
V108I 387 (23.4) 183 (17.2) <0.0001 570 (21.0)
Y181C/I 288 (17.4) 106 (10.0) <0.0001 394 (14.5)
G190A/S 155 (9.4) 46 (4.3) <0.0001 201 (7.4)
Protease
L90M 337 (20.4) 126 (11.8) <0.0001 463 (17.0)
M46I/L 302 (18.3) 131 (12.3) <0.0001 433 (15.9)
V82A/F/T/S 269 (16.3) 98 (9.2) <0.0001 367 (13.5)
I84V 123 (7.4) 59 (5.5) 0.05 182 (6.7)
aFDCAs period: Pre FDCAs: patients with genotypical resistance test made from January 2002 to June 2005; Post FDCAs patients with genotypical resistance test made from July 2005 to June 2008.
bp value from chi-square test
cTAMS: Thymidine analog mutations: T215F/Y, M41L, D67N, L210W, K70R, K219Q/E
Table 2: Prevalence of the most frequently resistance associated mutations among HIV+ adult patients with virological failure in Catalonia by FDCAs Period.